[Effects of short-term treatment of somatostatin on angiogenesis of XXXX ].

@entity1 @entity7 @entity5 @entity189 @entity540 @entity7931 @entity356
BACKGROUND _ OBJECTIVE: It is a hot spot in @entity5 therapies to inhibit the angiogenesis of @entity189 . Our current study was designed to investigate the inhibitory effect of somatostatin analogue on the angiogenesis of @entity356 by hypodermic injection. METHODS: Twenty-five @entity1 who have positive expression of @entity7 and @entity7931 ( @entity7931 )were selected by gastroscopic biopsy and immunohistochemical staining before surgical operation. After 7 days of Sandostatin administration (10 microg/kg, hypodermic injection, twice a day), the @entity5 extirpations were made. During the Sandostatin treatment, the serum levels of @entity7 and the @entity540 were measured by enzyme-linked immunosorbant assay (ELISA) (d1,d3,d7, separately). Before and after operation,the expression levels of @entity7 and @entity540 were examined by Western blot analysis and the density of micro-vessels was determined by immunohistochemical staining. RESULTS: After a week of Sandostatin therapy,the concentration of @entity7 and @entity540 in serum was drastically diminished ( @entity7 :1.02+/-0.41 microg /L vs 1.88+/-0.87 microg/L, P< 0.05; @entity540 :0.88+/-0.32 ng/L vs 2.12+/-1.06 ng/L,P< 0.05). The expression levels of @entity7 (absorbance:1.306 vs 488,P< 0.01) and @entity540 (absorbance:1.287 vs 512,P< 0.01) were obviously decreased after the remedy. The density of micro-vessels turn to the less, but there was no statistical difference before and after operation(P >0.05). CONCLUSION: By the short-term therapy of sandostatin, the expression of @entity7 and @entity540 can be inhibited. There is a tendency that the serum levels of @entity7 and @entity540 decrease with the increase of therapy time.
